BTC $58270.6324
ETH $3301.4664
BNB $400.6794
SOL $110.0515
XRP $0.5824
ADA $0.6271
AVAX $39.6830
DOGE $0.0970
TRX $0.1429
wstETH $3808.1443
DOT $8.3586
LINK $19.1334
WETH $3305.4834
MATIC $1.0428
UNI $11.0186
WBTC $57881.0446
IMX $3.3465
ICP $13.0316
BCH $301.2119
LTC $74.8427
CAKE $3.2026
ETC $28.3635
FIL $7.9610
LEO $4.4139
RNDR $7.4060
KAS $0.1700
HBAR $0.1136
DAI $1.0002
ATOM $11.3163
INJ $41.0291
VET $0.0502
TON $2.1419
OKB $51.8401
STX $3.2222
LDO $3.5190
FDUSD $0.9951
XMR $138.3902
XLM $0.1221
ARB $1.8935
NEAR $3.9358
TIA $16.9317
GRT $0.2829
WEMIX $2.2582
ENS $22.5313
MKR $2167.8555
APEX $2.4646
THETA $1.9298
BTC $58270.6324
ETH $3301.4664
BNB $400.6794
SOL $110.0515
XRP $0.5824
ADA $0.6271
AVAX $39.6830
DOGE $0.0970
TRX $0.1429
wstETH $3808.1443
DOT $8.3586
LINK $19.1334
WETH $3305.4834
MATIC $1.0428
UNI $11.0186
WBTC $57881.0446
IMX $3.3465
ICP $13.0316
BCH $301.2119
LTC $74.8427
CAKE $3.2026
ETC $28.3635
FIL $7.9610
LEO $4.4139
RNDR $7.4060
KAS $0.1700
HBAR $0.1136
DAI $1.0002
ATOM $11.3163
INJ $41.0291
VET $0.0502
TON $2.1419
OKB $51.8401
STX $3.2222
LDO $3.5190
FDUSD $0.9951
XMR $138.3902
XLM $0.1221
ARB $1.8935
NEAR $3.9358
TIA $16.9317
GRT $0.2829
WEMIX $2.2582
ENS $22.5313
MKR $2167.8555
APEX $2.4646
THETA $1.9298
  • Catalog
  • Blog
  • Tor Relay
  • Jabber
  • One-Time notes
  • Temp Email
  • What is TOR?
  • We are in tor
  • Connecticut to launch psilocybin and ecstasy treatment programs in 2023


    In 2023, the US state of Connecticut plans to launch psilocybin mushroom and ecstasy treatment programs, which will be funded from the regional budget.

    The U.S. Food and Drug Administration (FDA) has developed an Expanded Drug Access Program to enable patients to access drugs that have been shown to be safe in Phase 1 clinical trials but not yet proven effective in human trials. The list of these medicines, in particular, includes psilocybin and MDMA. Therefore, in Connecticut, therapies using these substances will be carried out under the FDA program.

    First, the state is going to set up a psychedelic-euphoretic treatment trial project for 100 veterans suffering from depression or post-traumatic stress disorder. Psilocybin and MDMA will be given to combatants who have not been helped by traditional methods of dealing with these ailments. During the pilot program, specialists will collect data on the consequences of taking psychoactive substances in order to evaluate their effectiveness and develop effective treatment protocols.

    The government will fund the project until the US Drug Enforcement Division recognizes that MDMA and psilocybin have medicinal properties, thus removing these substances from Schedule I narcotic drugs, which includes substances that have no medical value. After that, the authorities will issue grants to private organizations to provide services in the field of psychedelic and euphoric therapy.

    In May 2022, Connecticut Governor Ned Lamont signed a decree creating an ecosystem in the state for psychedelic and ecstasy treatment. An advisory council has been formed in the region that will be responsible for the infrastructure needed for safe and affordable substance treatment. For example, for this it will be necessary to train a sufficient number of qualified doctors.

    Walter Dunn, assistant professor of psychiatry at the University of California, Los Angeles, believes that the success of the pilot program will push the governments of Connecticut and other American states to legalize medical psilocybin. The information obtained will allow officials to strike a balance between the safety, efficacy and availability of the psychedelic. Psilocybin is currently legal for medicinal use in only one region of the United States, Oregon.

    Author DeepWeb
    UK arrests software developers for tax evasion
    Iranian Cobalt Mirage "leaves" bookmarks GitHub

    Comments 0

    Add comment